Synopsis: Divi’s Laboratories is in focus after reporting Q4 growth, with a 9.5% rise in profit and a 13.4% increase in revenue YoY, along with a ₹30 dividend. However, brokerages are split. Citi and Morgan Stanley remain bullish with higher targets, while Kotak Securities is cautious due to valuation concerns and a slower near-term growth outlook.
The shares of a Large-Cap company specialising in the large-scale manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and nutraceutical ingredients, are in focus following their Q4 results and brokerage views.
With a market capitalisation of Rs. 1,81,474.32 crores in the day’s trade, the shares of Divis Laboratories Ltd jumped upto 0.89 percent, making a high of Rs. 6,946.60 per share compared to its previous closing price of Rs. 6,885.00 per share.
What Happened
Divis Laboratories, engaged in the large-scale manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and nutraceutical ingredients, is in focus following their Q4 results as follows:
Its Revenue from operations increased by 9.5 percent YoY from Rs. 2,585 Crores in Q4FY25 to Rs. 2,831 Crores in Q4FY26, and increased by 8.7 percent QoQ from Rs. 2,604 Crores in Q3FY26 to Rs. 2,831 Crores in Q4FY26.
Its Net Profit increased by 13.4 percent YoY from Rs. 662 Crores in Q4FY25 to Rs. 751 Crores in Q4FY26, and on a QoQ basis, it increased by 28.8 percent from Rs. 583 Crores in Q3FY26 to Rs. 751 Crores in Q4FY26.
The earnings per share (EPS) for the quarterly period stood at Rs. 28.29, compared to Rs. 24.94 in the previous year’s quarter. The company has also recommended a final dividend of Rs. 30/- (i.e. 1,500%) per equity share of face value Rs. 2/- each for the financial year 2025-26. The record date for the payment of dividends is July 24, 2026.
Brokerage Views
Citi On Divis Laboratories
Citi has maintained a “Buy” rating on Divi’s Laboratories with a target price of Rs. 9,140 with an upside potential of 33 percent from the previous day’s close. The brokerage believes the recent softness in Q4 performance is temporary and not a concern for the long-term outlook.
The management has reaffirmed its guidance for double-digit revenue growth in FY27, indicating confidence in sustained demand and operational strength. This outlook is supported by a strong product pipeline and ongoing expansion plans.
Citi continues to view Divi’s Laboratories as a top pick in the pharmaceutical sector, citing its robust fundamentals, growth visibility, and capex-led capacity expansion as key long-term drivers.
Morgan Stanley on Divis Laboratories
Morgan Stanley has maintained an “Overweight” rating on Divi’s Laboratories with a target price of Rs. 7,904 with an upside potential of 15 percent from the previous day’s close, indicating a positive outlook on the stock’s medium-term performance.
The brokerage expects custom synthesis to be the key growth driver going forward, as it expands the company’s presence in high-value contract manufacturing opportunities. Divi’s also aims to strengthen its position in the global peptide market.
It currently operates the largest solid-phase peptide synthesis (SPPS) capacity in India, and the ongoing capex cycle is expected to support stronger revenue growth, with acceleration likely from H2FY27 onwards.
Kotak Securities on Divis Laboratories
Kotak Securities has maintained a “Sell” rating on Divi’s Laboratories with a target price of Rs. 5,850 with a target price of Rs. 7,904 with an downside potential of 15 percent from the previous day’s close, indicating a cautious outlook on the stock.
The brokerage highlighted that growth has slowed in Q4, and it is awaiting new generic API launches to revive momentum. It also noted that progress in peptides and execution timelines for dedicated projects remain important for improving custom synthesis performance. Kotak added that current valuations already factor in expected improvements in the custom synthesis business, limiting near-term upside potential.
Company Overview & Others
Divi’s Laboratories Ltd is one of India’s leading pharmaceutical companies engaged in the manufacturing of active pharmaceutical ingredients (APIs) and intermediates. It is a major global supplier of APIs and custom synthesis (contract development and manufacturing services), catering to innovator and generic pharmaceutical companies across regulated and emerging markets.
The company is known for its strong capabilities in complex chemistry, large-scale manufacturing, and niche products such as peptides. With a strong export focus, advanced manufacturing facilities, and a reputation for quality and regulatory compliance, Divi’s has established itself as a key player in the global pharmaceutical value chain.
The company has strong profitability metrics, with a Return on Capital Employed (ROCE) of 22.0% and Return on Equity (ROE) of 16.5%, indicating efficient use of capital and decent returns generated for shareholders. These figures reflect stable operational performance and effective deployment of resources in its business.
On the financial strength side, the company operates with zero debt, as shown by a debt-to-equity ratio of 0.00, indicating a very strong balance sheet and low financial risk. It also maintains a healthy dividend payout of 39.0%, showing a consistent return of profits to shareholders while balancing reinvestment for growth.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Divis Lab Share: Should You Buy, Sell, or Hold After Q4 Results? appeared first on Trade Brains.